Drug profile · INN
lorlatinib
LORVIQUA
lorlatinib (LORVIQUA) is a eml4-alk inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lorlatinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
lorlatinib (LORVIQUA) is a eml4-alk inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
EML4-ALK inhibitor
Primary target: ALK tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lorlatinib?
lorlatinib (LORVIQUA) is a eml4-alk inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lorlatinib?
LORVIQUA is a marketed brand name for lorlatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lorlatinib?
lorlatinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.